Inside Operation ‘Cattitude': A Pet Food Giant's Mission to Understand Cats
So Mars launched a mission to get its dog-loving workers inside cats' heads.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBS News
32 minutes ago
- CBS News
"Back to the Future the Musical" brings theater magic to Boston
It's "Back to the Future" like you've never seen it before. The hit 80s movie is now celebrating its 40th anniversary and a musical version is on stage in Boston. On top of the Huey Lewis and the News classics, there are some new songs as well as your favorite lines and costumes, and of course, the DeLorean. Lucas Hallauer and David Josefsberg are the two latest actors to portray Marty McFly and Doc Brown. "It's an iconic movie and these characters are iconic, played by iconic actors," said Hallauer. "So there's a lot to live up to, but it's really fun to hear everyone's reaction and that nostalgia hit them. " Josefsberg said, "Being able to take something that's iconic and finding ways to put myself into it is something that I'll really I've learned from this and will be able to take forward." As Marty's mother, Lorraine, Methuen native Zan Berube knows Boston audiences are in for a fun night at the theater. "The car, the costumes, the sets, the video screen. It's so realistic. It's theater magic to its fullest extent. I remember sitting in the Broadway house and watching the show and being like, how are they doing that? I'm an actor. I've participated backstage. And I've worked one-on-one with crew. And I had no idea," Berube told WBZ-TV. Huge fan base from the beloved movie Hallauer explains, "We kind of started a win, because the characters are already so well loved and everyone wants to root for them." It's not an exact replica of the movie. But Bob Gale, the film's co-writer, wrote the musical as well. "You can't say, 'oh, this is not what their creator would have wanted,' because it is the creator," explained Josefsberg. "I'm grateful to be involved in something with such a big fan base and a big following," Hallauer said. Berube says that the following includes the film's stars. "Lea Thompson, the iconic, original Lorraine Banes. It's big shoes to fill, right? I got to meet her opening night when we were in Los Angeles. She greeted me after the show with the biggest hug and was like, 'You did it. You're doing it. Good job,' And oh my gosh, that was the biggest compliment I could have ever received." Josefsberg said the crowds in Boston are "Smart. They get the jokes, they get the humor, they get everything." Berube agreed, "It's been really fun, not only because it's my home city, but I think the audiences are really engaged and excited that the show is here."
CBS News
32 minutes ago
- CBS News
1880 shipwreck is discovered by accident in Wisconsin river
A survey of a Wisconsin river led to the accidental discovery of a shipwreck that sank in the area over a century ago. The Wisconsin Historical Society's Maritime Preservation Program and the Wisconsin Underwater Archaeology Association were conducting a high-resolution sonar survey earlier this year of the Fox River to map "potential cultural sites" in a 2.5-mile stretch of the waterway, the historical society said on social media. Those sites included the wreck of a steamer that sank in 1870 and the identified wreck of a ship that had been surveyed in 2016. Using a sonar system that creates a 3D rendering of the river bottom, the researchers were able to map the entire section of the river in high resolution, the archaeology association said. The stretch that the team mapped has "a significant amount" of debris, the researchers said, including large trees, rocks and remnants of lumber rafts and collapsed bridges. But amid the debris, they were surprised to see the remains of what appeared to be a different ship. "That's the excitement of archaeology, sometimes we find something new that we were not looking for!" the Wisconsin Historical Society said. The scan revealed a partially buried ship's hull about 90 feet long and 23 feet wide. The wreck is likely that of the L.W. Crane, the Wisconsin Historical Society said. The ship is of a different size than the 1870 wreck the team was initially looking for. The L.W. Crane was a wooden paddle wheel steamer ship built in Berlin, Wisconsin, in 1865, the historical society said. It was used to transport passengers and freight between Green Bay and Oconto. In 1880, the ship caught fire, burned to the waterline and sank in Oshkosh. The site where it sank is directly across the river from where the wreck was found. The historical society did not say how the ship caught fire, or if anyone was aboard the vessel at the time. Further investigations at the waterway are ongoing, the Wisconsin Underwater Archaeology Association said, but are hindered by the debris at the bottom of the river. The researchers are working to find more information about the steamer that sank in 1870, as well as the L.W. Crane and other wrecks in the area.
Yahoo
33 minutes ago
- Yahoo
60 Degrees Pharmaceuticals to Submit MUMS (Minor Use/Minor Species) Designation Request to FDA for Tafenoquine for Acute Canine Babesiosis in 2025
Data from three independent clinical studies demonstrate utility of tafenoquine to treat acute canine babesiosis WASHINGTON, July 14, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) ('60 Degrees' or the 'Company'), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced that the Company will conduct a gap analysis of its existing data prior to submitting a Minor Use Minor Species (MUMS) designation request to the United States Food and Drug Administration (FDA) for tafenoquine for the treatment of acute canine babesiosis. The submission will be based on results of three clinical efficacy studies that evaluated ARAKODA® (tafenoquine) for canine babesiosis, and existing canine safety data and chemistry manufacturing and controls (CMC) data for tafenoquine generated through the clinical development of ARAKODA for malaria. The clinical efficacy studies involved experimental Babesia infections and dogs diagnosed with naturally acquired Babesia infection in veterinary clinics. One of the studies was company-sponsored and conducted at North Carolina State University. Collectively, the studies showed that tafenoquine, administered as ARAKODA tablets, was well tolerated and appeared to facilitate recovery from acute infection. Every year in the United States, several hundred to several thousand cases of canine babesiosis are seen. It is an emerging tick-borne illness carried by the same tick vector as Lyme Disease. No FDA-approved oral treatment for canine babesiosis exists, and currently available treatments carry significant toxicity risk or the propensity to generate drug resistance. 'Data from the canine babesiosis studies are impactful when viewed in the larger context of the ground-breaking human babesiosis research we are now sponsoring,' said Chief Executive Officer of 60 Degrees Pharmaceuticals, Geoff Dow. 'The positive findings of the canine babesiosis study are in line with our earlier findings that tafenoquine could be effective against babesiosis in humans.' About ARAKODA® (tafenoquine)Tafenoquine was discovered by Walter Reed Army Institute of Research. Tafenoquine was approved for malaria prophylaxis in 2018 in the United States as ARAKODA® and in Australia as KODATEF®. Both were commercially launched in 2019 and are currently distributed through pharmaceutical wholesaler networks in each respective country. They are available at retail pharmacies as a prescription-only malaria prevention drug. According to the Centers for Disease Control and Prevention, the long terminal half-life of tafenoquine, which is approximately 16 days, offers the advantage of less frequent dosing for the prophylaxis of malaria. ARAKODA® is not suitable for everyone, and patients and prescribers should review the Important Safety Information below. Individuals at risk of contracting malaria are prescribed ARAKODA® 2 x 100 mg tablets once per day for three days (the loading phase) prior to travel to an area of the world where malaria is endemic, 2 x 100 mg tablets weekly for up to six months during travel, then 2 x 100 mg in the week following travel. Tafenoquine has not been proven to be effective for treatment or prevention of babesiosis and is not approved by the U.S. Food and Drug Administration for such an indication. ARAKODA® (tafenoquine) Important Safety Information ARAKODA® is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years and older. Contraindications ARAKODA® should not be administered to: Glucose-6-phosphate dehydrogenase ('G6PD') deficiency or unknown G6PD status; Breastfeeding by a lactating woman when the infant is found to be G6PD deficient or if G6PD status is unknown; Patients with a history of psychotic disorders or current psychotic symptoms; or Known hypersensitivity reactions to tafenoquine, other 8-aminoquinolines, or any component of ARAKODA®. Warnings and Precautions Hemolytic Anemia: G6PD testing must be performed before prescribing ARAKODA® due to the risk of hemolytic anemia. Monitor patients for signs or symptoms of hemolysis. G6PD Deficiency in Pregnancy or Lactation: ARAKODA® may cause fetal harm when administered to a pregnant woman with a G6PD-deficient fetus. ARAKODA® is not recommended during pregnancy. A G6PD-deficient infant may be at risk for hemolytic anemia from exposure to ARAKODA® through breast milk. Check infant's G6PD status before breastfeeding begins. Methemoglobinemia: Asymptomatic elevations in blood methemoglobin have been observed. Initiate appropriate therapy if signs or symptoms of methemoglobinemia occur. Psychiatric Effects: Serious psychotic adverse reactions have been observed in patients with a history of psychosis or schizophrenia, at doses different from the approved dose. If psychotic symptoms (hallucinations, delusions, or grossly disorganized thinking or behavior) occur, consider discontinuation of ARAKODA® therapy and evaluation by a mental health professional as soon as possible. Hypersensitivity Reactions: Serious hypersensitivity reactions have been observed with administration of ARAKODA®. If hypersensitivity reactions occur, institute appropriate therapy. Delayed Adverse Reactions: Due to the long half-life of ARAKODA® (approximately 16 days), psychiatric effects, hemolytic anemia, methemoglobinemia, and hypersensitivity reactions may be delayed in onset and/or duration. Adverse Reactions: The most common adverse reactions (incidence greater than or equal to 1 percent) were: headache, dizziness, back pain, diarrhea, nausea, vomiting, increased alanine aminotransferase (ALT), motion sickness, insomnia, depression, abnormal dreams, and anxiety. Drug Interactions Avoid co-administration with drugs that are substrates of organic cation transporter-2 or multidrug and toxin extrusion transporters. Use in Specific Populations Lactation: Advise women not to breastfeed a G6PD-deficient infant or infant with unknown G6PD status during treatment and for 3 months after the last dose of ARAKODA®. To report SUSPECTED ADVERSE REACTIONS, contact 60 Degrees Pharmaceuticals, Inc. at 1- 888-834-0225 or the FDA at 1-800-FDA-1088 or The full prescribing information of ARAKODA® is located here. About 60 Degrees Pharmaceuticals, Inc.60 Degrees Pharmaceuticals, Inc., founded in 2010, specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases that affect the lives of millions of people. 60 Degrees Pharmaceuticals, Inc. achieved FDA approval of its lead product, ARAKODA® (tafenoquine), for malaria prevention, in 2018. 60 Degrees Pharmaceuticals, Inc. also collaborates with prominent research organizations in the U.S., Australia, and Singapore. The 60 Degrees Pharmaceuticals, Inc. mission has been supported through in-kind funding from the U.S. Department of Defense and private institutional investors including Knight Therapeutics Inc., a Canadian-based pan-American specialty pharmaceutical company. 60 Degrees Pharmaceuticals, Inc. is headquartered in Washington D.C., with a majority-owned subsidiary in Australia. Learn more at The statements contained herein may include prospects, statements of future expectations and other forward-looking statements that are based on management's current views and assumptions and involve known and unknown risks and uncertainties. Actual results, performance or events may differ materially from those expressed or implied in such forward-looking statements. Cautionary Note Regarding Forward-Looking StatementsThis press release may contain 'forward-looking statements' within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward‐looking statements reflect the current view about future events. When used in this press release, the words 'anticipate,' 'believe,' 'estimate,' 'expect,' 'future,' 'intend,' 'plan,' or the negative of these terms and similar expressions, as they relate to us or our management, identify forward‐looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: there is substantial doubt as to our ability to continue on a going-concern basis; we might not be eligible for Australian government research and development tax rebates; if we are not able to successfully develop, obtain FDA approval for, and provide for the commercialization of non-malaria prevention indications for tafenoquine (ARAKODA® or other regimen) or Celgosivir in a timely manner, we may not be able to expand our business operations; we may not be able to successfully conduct planned clinical trials or patient recruitment in our trials might be slow or negligible; and we have no manufacturing capacity which puts us at risk of lengthy and costly delays of bringing our products to market. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission ('SEC'), including the information contained in our Annual Report on Form 10-K filed with the SEC on April 1, 2024, and our subsequent SEC filings. Investors and security holders are urged to read these documents free of charge on the SEC's website at As a result of these matters, changes in facts, assumptions not being realized or other circumstances, the Company's actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. Media Contacts:Sheila A. BurkeSheilaBurke-consultant@ 667-6330 Investor Contact:Patrick Gaynespatrickgaynes@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
